2,705,151 Shares in Pediatrix Medical Group, Inc. (NYSE:MD) Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. acquired a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,705,151 shares of the company's stock, valued at approximately $35,492,000. Pacer Advisors Inc. owned about 3.15% of Pediatrix Medical Group at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Dana Investment Advisors Inc. lifted its stake in Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock valued at $7,725,000 after buying an additional 455,785 shares during the period. Weiss Asset Management LP lifted its position in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company's stock valued at $10,580,000 after acquiring an additional 306,143 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company's stock worth $2,192,000 after acquiring an additional 251,072 shares in the last quarter. RBF Capital LLC acquired a new stake in Pediatrix Medical Group in the third quarter worth $1,695,000. Finally, Rubric Capital Management LP increased its stake in Pediatrix Medical Group by 1.5% in the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company's stock valued at $95,907,000 after purchasing an additional 125,000 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company's stock.

Insider Transactions at Pediatrix Medical Group

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the company's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mark S. Ordan sold 27,600 shares of the business's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Pediatrix Medical Group Stock Performance

Shares of NYSE:MD traded down $0.44 during mid-day trading on Friday, reaching $13.97. The company had a trading volume of 252,700 shares, compared to its average volume of 475,026. Pediatrix Medical Group, Inc. has a one year low of $6.62 and a one year high of $16.41. The company's 50-day moving average price is $13.98 and its 200-day moving average price is $12.24. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -4.57, a PEG ratio of 1.43 and a beta of 1.58.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period in the prior year, the firm posted $0.29 earnings per share. The company's revenue for the quarter was up .9% on a year-over-year basis. As a group, equities research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MD has been the subject of a number of research analyst reports. Truist Financial decreased their target price on Pediatrix Medical Group from $16.00 to $15.00 and set a "hold" rating for the company in a research report on Monday, January 6th. Macquarie began coverage on Pediatrix Medical Group in a research report on Monday, December 16th. They set an "outperform" rating and a $18.00 target price on the stock. UBS Group lifted their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Jefferies Financial Group boosted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a "hold" rating to a "buy" rating in a research note on Wednesday, January 22nd. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $16.25.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.